Will Maddox

A pivotal study of a Takeda primary immunodeficiency disease (PID) asset has hit its primary endpoint, demonstrating pharmacokinetic (PK) comparability between the asset and the company’s HyQvia, w

For people living with exocrine pancreatic insufficiency (EPI) due to cystic fibrosis (CF), the only treatment option is a regimen that can include up to 40 pills a da

Welcome to this week's Chutes & Ladders, our roundup of significant leadership hirings, firings and retirings across the industry.

One day in early May, web-based prediction market platform Kalshi listed two contracts tied to Compass Pathways’ psilocybin drug, COMP360.

Kordata Dynamics is emerging from stealth with the aim to redefine clinical trial execution by processing neural data while taking advantage of the FDA's recent push for real-time clinical trials.

Irish CRO Icon has closed the book on its investigation into its accounting practices and restated its consolidated financials for 2023 and 2024.

Welcome to this week's Chutes & Ladders, our roundup of significant leadership hirings, firings and retirings across the industry.

The American Society of Clinical Oncology (ASCO) and Ryght AI are teaming up to identify research sites for an ASCO clinical trial evaluating starting doses of CDK4/6 inhibitors in patients with metastatic breast cancer.

Travere Therapeutics has set its sights on Everest Medicines' therapy for rare kidney diseases, paying $112.5 million upfront for a drug that has already begun the trek into the clinic.